Toni Choueiri, MD

Medical Oncology

Toni Choueiri, MD

View Full Profile

Related Videos

ASCO26: Toni Choueiri, MD, KEYNOTE-654 Video

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ...

2026 ASCO Kidney Cancer Highlights Video

2026 ASCO Kidney Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates

Kidney Cancer Highlights from ASCO 2025 Video

Kidney Cancer Highlights from ASCO 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2025.

ARC-20 Study Presented by Toni Choueiri, MD. Video

ARC-20 Study Presented by Toni Choueiri, MD.

Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.

Checkmate 214 Presented by Toni Choueiri, MD. Video

Checkmate 214 Presented by Toni Choueiri, MD.

Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial.

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan Video

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101 Video

Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101

Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.

Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis Video

Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis

Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.

Kidney Cancer Highlights from ESMO 2023 Video

Kidney Cancer Highlights from ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.